Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520789 | 1.00 | TACR3 (0.52) | TACR3 | |
| SCHEMBL1441647 | 0.90 | TACR3 (0.66) | TACR3 | |
| SCHEMBL1441644 | 0.90 | TACR3 (0.66) | TACR3 | |
| SCHEMBL6526770 | 0.87 | TACR3 (0.60) | TACR3 | |
| SCHEMBL6526774 | 0.87 | TACR3 (0.60) | TACR3 | |
| SCHEMBL1441469 | 0.87 | TACR3 (0.64) | TACR3 | |
| SCHEMBL12789433 | 0.87 | TACR3 (0.64) | TACR3 | |
| SCHEMBL12847188 | 0.84 | TACR3 (0.45) | TACR3 | |
| SCHEMBL1439340 | 0.84 | TACR3 (0.61) | TACR3 | |
| SCHEMBL1439342 | 0.84 | TACR3 (0.61) | TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470524-B1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-07-24 | — | — | EP | disclosed |
| EP-2470524-B1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8394834-B2 | Pyrrolidines as NK3 receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394834-B2 | Pyrrolidines as NK3 receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394834-B2 | Pyrrolidines as NK3 receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110053948-A1 | PYRROLIDINES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110053948-A1 | PYRROLIDINES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110053948-A1 | PYRROLIDINES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053948-A1 | PYRROLIDINES AS NK3 RECEPTOR ANTAGONISTS | OPRM1, OPRK1, OPRL1 | TACR3 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.